Pharmaceutical Executive-10-01-2008

Manufacturers overpay PBMs millions of dollars each year in rebates overpayments. Here's how to stop the leakage.

It's management makeover time-and micromanaging is so last year.

Japan is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success?

Try this one on for size: Multi-tasking isn't the path to greatness

Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.

Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems

What's the buzz all about? Word of mouth is more effective than we think.

Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug.

A head-to-head comparison of the Drug Vote '08

Web analystics is helping a new generation of pharma web sites get engaged.

A vision of pharma's next business model is starting to emerge. But how do we get from here to there?

Congressional leaders ready campaign to curb Medicare drug plans.

Enter the Maturity Matrix: the future of KOL management organization.

Cubist Pharmaceuticals CEO Michael Bonney has given the company a successful start-and is now predicting the future of drug resistance.

Clinical trials need to change. A recent survey shows that industry should address the research supply chain for the greatest gains in effciency.